GenCore version 5.1.3


OM nucleic - nucleic search, using sw model

Run on: October 26, 2002, 20:33:06 ; Search time 244 Seconds
(without alignments)
4876.318 Million cell updates/sec

Title: US-09-840-795-18_COPY_78_770
Perfect score: 693
Sequence: 1 atggattgccaagaaaatga.....agcagcaggggcctgaaatg 693

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| | Result No. | Score | % Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|---|
| | 1 | 693 | 100.0 | 932 | 21 | AAZ92411 | cDNA encoding huma |
| | 2 | 685 | 98.8 | 3861 | 22 | AAF27998 | Human TR14 recepto |
| | 3 | 668.4 | 96.5 | 3152 | 22 | AAF28049 | Human TR14 coding |
| | 4 | 611.4 | 88.2 | 1162 | 22 | AAS05944 | Human uterine myom |
| | 5 | 609.4 | 87.9 | 899 | 22 | AAC63993 | Human TNFR homolog |
| c | 6 | 609.4 | 87.9 | 899 | 22 | AAC63994 | Human TNFR homolog |
| | 7 | 593.4 | 85.6 | 905 | 21 | AAC62232 | cDNA encoding a hu |
| | 8 | 593.4 | 85.6 | 905 | 21 | AAC58642 | Human PRO5727 prot |
| | 9 | 593.4 | 85.6 | 905 | 22 | AAC63991 | Human TNFR homolog |
| c | 10 | 593.4 | 85.6 | 905 | 22 | AAC63992 | Human TNFR homolog |
| | 11 | 518 | 74.7 | 1550 | 21 | AAA47453 | Human TANGO 140-1 |
| | 12 | 446.6 | 64.4 | 891 | 22 | AAS05960 | Degenerate cDNA se |
| | 13 | 446.4 | 64.4 | 807 | 22 | AAS05945 | Human uterine myom |
| | 14 | 427.4 | 61.7 | 3385 | 21 | AAA47454 | Human TANGO 140-2 |
| | 15 | 413.2 | 59.6 | 1081 | 22 | AAS05973 | Expression vector |
| | 16 | 393.2 | 56.7 | 534 | 22 | AAS05954 | Human soluble ztnf |
| | 17 | 393.2 | 56.7 | 1200 | 22 | AAS05955 | Human soluble ztnf |
| | 18 | 317.4 | 45.8 | 801 | 22 | AAS05961 | Degenerate cDNA se |
| | 19 | 315.4 | 45.5 | 519 | 22 | AAS05966 | Degenerate DNA seq |
| | 20 | 257 | 37.1 | 528 | 22 | AAS05964 | Polynucleotide seq |
| | 21 | 248.2 | 35.8 | 546 | 21 | AAZ92410 | cDNA encoding huma |
| | 22 | 248.2 | 35.8 | 546 | 22 | AAF28012 | Human TR14 coding |
| | 23 | 229.6 | 33.1 | 474 | 21 | AAZ92409 | cDNA encoding huma |
| | 24 | 229.6 | 33.1 | 474 | 22 | AAF28013 | Human TR14 coding |
| | 25 | 220.4 | 31.8 | 529 | 22 | AAS05962 | Human UMLR polynuc |
| | 26 | 188 | 27.1 | 292 | 21 | AAC62225 | Nucleotide sequenc |
| | 27 | 188 | 27.1 | 292 | 22 | AAC63995 | Human TNFR homolog |
| | 28 | 163.2 | 23.5 | 645 | 21 | AAA90154 | Murine dTroy gene. |
| | 29 | 163.2 | 23.5 | 886 | 20 | AAX23414 | Mouse mAPO4-alpha |
| | 30 | 163.2 | 23.5 | 942 | 20 | AAX24977 | Mouse TRAIN-R (lon |
| | 31 | 163.2 | 23.5 | 981 | 20 | AAX87394 | Mouse STRIFE1 (Tan |
| | 32 | 163.2 | 23.5 | 1678 | 20 | AAX23413 | Mouse mAPO4-alpha |
| | 33 | 163.2 | 23.5 | 1914 | 22 | AAS08985 | Murine TRADE cDNA. |
| | 34 | 163.2 | 23.5 | 4089 | 21 | AAA90147 | Murine Troy gene. |
| | 35 | 156.4 | 22.6 | 1272 | 21 | AAA90148 | Human Troy gene. |
| | 36 | 156.4 | 22.6 | 1489 | 20 | AAX23415 | Human hAPO4-alpha |
| | 37 | 154.8 | 22.3 | 987 | 20 | AAX59346 | Human NTR-5 cDNA. |
| | 38 | 154.8 | 22.3 | 1254 | 22 | AAF90463 | Human tumour necro |
| | 39 | 154.8 | 22.3 | 1325 | 22 | AAS08984 | Human TRADE-beta c |
| | 40 | 154.8 | 22.3 | 1496 | 19 | AAV33362 | Nucleotide sequenc |
| | 41 | 154.8 | 22.3 | 1502 | 20 | AAX08689 | Novel nucleotide s |
| | 42 | 154.8 | 22.3 | 1660 | 22 | AAS08983 | Human TRADE-alpha |
| | 43 | 154.8 | 22.3 | 1704 | 19 | AAV33361 | Nucleotide sequenc |
| | 44 | 154.8 | 22.3 | 2185 | 20 | AAX24978 | Human TRAIN-R cDNA |
| | 45 | 154.8 | 22.3 | 2870 | 21 | AAC58639 | Human PRO4333 prot |

ALIGNMENTS

RESULT 1
AAZ92411
ID AAZ92411 standard; cDNA; 932 BP.
XX
AC AAZ92411;
XX
DT 05-JUN-2000 (first entry)
XX
DE cDNA encoding human Rank-like protein RANKL, SEQ ID NO:22.
XX
KW TNF receptor family; tumour necrosis factor; HDTEA84; HSLJD37R;
KW Rank-like protein; RANKL; immune disorder; inflammation; allergy;
KW immunosuppressant; antiarthritic; antirheumatoid; antiinflammatory;
KW dermatological; antithyroid; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 78..773
FT /*tag= a
FT /product= "Human RANKL"
XX
PN WO200001817-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-US12366.
XX
PR 06-JUL-1998; 98US-0110938.
PR 13-JUL-1998; 98US-0114466.
PR 23-JUL-1998; 98US-0093897.
PR 12-AUG-1998; 98US-0132968.

PR 18-AUG-1998; 98US-0136214.
PR 11-SEP-1998; 98US-0099999.
XX
PA (SCHE ) SCHERING CORP.
XX
PI Bates EEM, Lebecque SJE, Murphy EE, Mattson JD, Gorman DM;
PI Hedrick JA, Wang L, Zlotnik A, Murgolo NJ, Greene JR, Johnston JA;
PI Bazan JF, Mahony D, Lees EM;
XX
DR WPI; 2000-171015/15.
DR P-PSDB; AAY77468.
XX
PT New isolated mammalian genes, used to develop products for treating
PT e.g. immune, inflammatory or allergic abnormalities, cancers or
PT degenerative conditions -
XX
PS Claim 25; Page 176-177; 218pp; English.
XX
CC The invention relates to a number of primate and/or rodent proteins, and
CC the genes which encode them. The invention encompasses human dendritic
CC cell prostaglandin transporter (DC-PGT); the TNF (tumour necrosis
CC factor) receptor family-related proteins HDTEA84, HSLJD37R and RANKL;
CC human CC chemokine HCC5; human deubiquitinating proteins Dub11 and Dub
CC 12; human MD-1 and human and murine MD-2 proteins, which exhibit the
CC properties of ligands for proteins comprising a leucine-rich motif
CC (LRR); human cyclin E2; cDNAs encoding these proteins; and antibodies
CC against these proteins. The proteins can be used for modulating the
CC physiology or development of a cell. They can be used to mediate uptake
CC of substrates (e.g., prostaglandin-like molecules), to modulate or
CC mediate cellular interactions (e.g., induce or prevent trafficking,
CC proliferation, or differentiation of cells), or are intracellular
CC proteins which are important in various cellular processes such as the
CC deubiquitination of proteins or cell cycle regulation. The products can
CC be used for treating medical conditions such as immune, inflammatory or
CC allergic disorders, or abnormal cellular proliferation, for example,
CC cancers or degenerative conditions. They can be used to modulate immune
CC responses in disease states e.g., autoimmune disorders, including
CC rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's
CC autoimmune thyroiditis, as well as acute and chronic inflammatory
CC responses in which T cell activation, expansion, and/or immunological T
CC cell memory play an important role. Sequences AAZ92404-Z92411 represent
CC cDNAs encoding TNF receptor family-related proteins. AAZ92404 encodes the
CC human protein HDTEA84, AAZ92405-Z92407 encode human HSLJD37R proteins,
CC AAZ92408 encodes murine Rank-like protein RANKL, and AAZ92409-Z92411
CC encode human RANKL proteins.
XX
SQ Sequence 932 BP; 205 A; 260 C; 246 G; 220 T; 1 other;

Query Match 100.0%; Score 693; DB 21; Length 932;
Best Local Similarity 100.0%; Pred. No. 6.9e-198;
Matches 693; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      78 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 137

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     138 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 197

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     198 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 257

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     258 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 317

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     318 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 377

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     378 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 437

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     438 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 497

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     498 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 557

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     558 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 617

Qy     541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     618 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 677

Qy     601 GAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGTT 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     678 GAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGTT 737

Qy     661 CCTATACCACAACAGCAGCAGGGGCCTGAAATG 693
          |||||||||||||||||||||||||||||||||
Db     738 CCTATACCACAACAGCAGCAGGGGCCTGAAATG 770
```

RESULT 2
AAF27998
ID AAF27998 standard; DNA; 3861 BP.
XX
AC AAF27998;
XX
DT 08-MAY-2001 (first entry)
XX
DE Human TR14 receptor coding sequence SEQ ID NO: 4.
XX
KW Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW cancer; autoimmune disease; allergy; inflammatory disease;
KW graft rejection; apoptosis; cardiovascular disease; aneurysm; ds.
XX
OS Homo sapiens.
XX
PN WO200105834-A1.
XX
PD 25-JAN-2001.
XX
PF 14-JUL-2000; 2000WO-US19343.
XX
PR 16-JUL-1999; 99US-0144087.
PR 18-AUG-1999; 99US-0149450.
PR 20-AUG-1999; 99US-0149712.
PR 10-SEP-1999; 99US-0153089.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Young PE;
XX
DR WPI; 2001-112682/12.
DR P-PSDB; AAB35330.
XX
PT Nucleic acids encoding 2 human tumor necrosis factor receptor
PT polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT hypohidrotic ectodermal dysplasia -
XX
PS Example 7; Page 373-376; 418pp; English.
XX
CC The present invention provides the protein and coding sequences of the
CC human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC useful in the diagnosis and treatment of many diseases, including cancer,
CC autoimmune diseases, cardiovascular disorders, allergies,

```
CC   neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC   infections.
XX
SQ   Sequence 3861 BP; 992 A; 929 C; 860 G; 1071 T; 9 other;

  Query Match             98.8%;  Score 685;  DB 22;  Length 3861;
  Best Local Similarity   99.3%;  Pred. No. 3.3e-195;
  Matches  688;  Conservative    0;  Mismatches    5;  Indels    0;  Gaps    0;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3166 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 3225

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3226 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 3285

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          ||||||||||||||||||||||    ||| ||||||||||||||||||||||||||||||
Db    3286 TGCACAGCCTGCCCTCCTCGCAGTACAAAAGGCAGCTGGGGCCACCACAAATGTCAGAGT 3345

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3346 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 3405

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3406 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 3465

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3466 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 3525

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3526 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 3585

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3586 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 3645

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3646 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 3705

Qy     541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3706 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 3765

Qy     601 GAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGTT 660
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    3766 GAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGTT 3825

Qy     661 CCTATACCACAACAGCAGCAGGGGCCTGAAATG 693
          |||||||||||||||||||||||||||||||||
Db    3826 CCTATACCACAACAGCAGCAGGGGCCTGAAATG 3858


RESULT 3
AAF28049
ID   AAF28049 standard; DNA; 3152 BP.
XX
AC   AAF28049;
XX
DT   08-MAY-2001  (first entry)
XX
DE   Human TR14 coding sequence SEQ ID NO: 60.
XX
KW   Human; tumour necrosis factor receptor; TR13; TR14; infection;
KW   cancer; autoimmune disease; allergy; inflammatory disease;
KW   graft rejection; apoptosis; cardiovascular disease; aneurysm; ds.
XX
OS   Homo sapiens.
XX
PN   WO200105834-A1.
XX
PD   25-JAN-2001.
XX
PF   14-JUL-2000; 2000WO-US19343.
XX
PR   16-JUL-1999;   99US-0144087.
PR   18-AUG-1999;   99US-0149450.
PR   20-AUG-1999;   99US-0149712.
PR   10-SEP-1999;   99US-0153089.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Ni J,  Young PE;
XX
DR   WPI; 2001-112682/12.
DR   P-PSDB; AAB35335.
XX
PT   Nucleic acids encoding 2 human tumor necrosis factor receptor
PT   polypeptides ((TR13) and (TR14)), useful for the prevention, diagnosis
PT   and treatment of, e.g. cancers, acquired immune deficiency syndrome and
PT   hypohidrotic ectodermal dysplasia -
XX
PS   Claim 6; Page 412-413; 418pp; English.
XX
CC   The present invention provides the protein and coding sequences of the
CC   human tumour necrosis factor receptors TR13 and TR14. These sequences are
CC   useful in the diagnosis and treatment of many diseases, including cancer,
CC   autoimmune diseases, cardiovascular disorders, allergies,
CC   neurodegenerative diseases, graft rejection, inflammation, aneurysms and
CC   infections.
XX
SQ   Sequence 3152 BP; 840 A; 739 C; 663 G; 908 T; 2 other;

  Query Match             96.5%;  Score 668.4;  DB 22;  Length 3152;
  Best Local Similarity   99.6%;  Pred. No. 2.9e-190;
  Matches  691;  Conservative    0;  Mismatches    1;  Indels    2;  Gaps    2;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      67 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 126

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     127 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 186

Qy     121 T-GCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAG 179
          | ||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||
Db     187 TGGCACAGCCTGCCCTCCTCGCA-GTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAG 245

Qy     180 TTGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAA 239
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     246 TTGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACACCTACCTCTAA 305

Qy     240 TGCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCA 299
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     306 TGCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCA 365

Qy     300 GGACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTT 359
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     366 GGACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTT 425

Qy     360 CCAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGT 419
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     426 CCAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGT 485

Qy     420 TGCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCT 479
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     486 TGCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCT 545

Qy     480 CTACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGC 539
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db     546 CTACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGC 605

Qy     540 TGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGC 599
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     606 TGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGC 665

Qy     600 TGAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGT 659
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     666 TGAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGT 725

Qy     660 TCCTATACCACAACAGCAGCAGGGGCCTGAAATG 693
           |||||||||||||||||||||||||||||||||
Db     726 TCCTATACCACAACAGCAGCAGGGGCCTGAAATG 759
```

```
RESULT 4
AAS05944
ID   AAS05944 standard; cDNA; 1162 BP.
XX
AC   AAS05944;
XX
DT   07-SEP-2001  (first entry)
XX
DE   Human uterine myometrium leiomyoma receptor (UMLR) cDNA sequence.
XX
KW   Human; uterine myometrium leiomyoma receptor; UMLR; ztnfr11;
KW   tumour necrosis factor receptor; TNFR; chromosome Xq11-q12; lung cancer;
KW   breast carcinoma; uterus melanoma; osteosarcoma; lymphoma; wound healing;
KW   gene therapy; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             104..913
FT                   /*tag= a
FT                   /product= "UMLR"
FT                   /note= "Also known as ztnfr11"
XX
PN   WO200130850-A1.
XX
PD   03-MAY-2001.
XX
PF   23-OCT-2000; 2000WO-US29304.
XX
PR   22-OCT-1999;   99US-0160880.
PR   02-NOV-1999;   99US-0163215.
PR   17-JUL-2000; 2000US-0218769.
PR   01-AUG-2000; 2000US-0222221.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Xu W,  Lofton-Day CE,  Henne R,  Presnell SR,  Yao Y,  Novak JE;
PI   Foster DC,  Yee DP;
XX
DR   WPI; 2001-300488/31.
DR   P-PSDB; AAU03106.
XX
PT   Uterine myometrium leiomyoma receptor polypeptides and polynucleotides
PT   for modulating inflammation, tumour growth, metastasis, cellular
PT   maturation, detecting modulators and as diagnostic indicators of cancer
PT   -
XX
PS   Claim 9; Page 114-116; 148pp; English.
XX
CC   The present sequence encoding for a novel human uterine myometrium
CC   leiomyoma receptor (UMLR) is a member of the tumour necrosis factor
CC   receptor (TNFR) family. The UMLR (also known as ztnfr11) gene maps to
CC   chromosome Xq11-q12. Amino acid residues of UMLR involved in ligand
CC   binding, consisting of residues 1-X (where X is 129-136) are useful
CC   for inhibiting the quantity of lung, breast carcinoma, melanoma,
CC   osteosarcoma or lymphoma cells expressing UMLR protein. UMLR polypeptides
CC   or its fragments are useful diagnostically or therapeutically for
CC   identifying tumour cells in uterus melanoma and lung cancer, for
CC   promoting wound healing, and for generating vaccines for cancer therapy.
CC   They are also useful for studying cell-cell interactions, apoptosis,
CC   fertilisation, development, immune recognition, growth control, tumour
CC   suppression and embryo maturation in vitro and in vivo, and for treating
CC   disorders associated with them. UMLR is also useful for identifying
CC   inhibitors of its activity, and for preparing antibodies which can be
CC   used to detect UMLR expression. UMLR polynucleotide sequences are useful
CC   as probes or primers as diagnostic indicators of cancer and for gene
CC   therapy.
XX
SQ   Sequence 1162 BP; 255 A; 327 C; 314 G; 266 T; 0 other;
```

```
  Query Match             88.2%;  Score 611.4;  DB 22;  Length 1162;
  Best Local Similarity   99.0%;  Pred. No. 2.4e-173;
  Matches  615;  Conservative    0;  Mismatches    6;  Indels    0;  Gaps    0;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     104 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 163

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     164 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 223

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     224 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 283

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     284 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 343

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     344 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 403

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     404 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 463

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     464 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 523

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     524 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 583

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     584 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 643

Qy     541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     644 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 703

Qy     601 GAGTCCCAAGTCTCTTGGGCC 621
           |||||||||| || ||  ||
Db     704 GAGTCCCAAGAGTCCTTTACC 724
```

```
RESULT 5
AAC63993
ID   AAC63993 standard; cDNA; 899 BP.
XX
AC   AAC63993;
XX
DT   14-FEB-2001  (first entry)
XX
DE   Human TNFR homologue clone DNA101848 cDNA.
XX
KW   Human; TNFR homologue; tumour necrosis factor receptor; DNA101848;
KW   apoptosis; NF-kappa-B activation; proinflammatory response;
```

```
KW   autoimmune response; modulation; antibody; EDA-A2 inhibition;
KW   gene mapping; antisense therapy; gene therapy; ATCC 203907; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061757-A1.
XX
PD   19-OCT-2000.
XX
PF   12-APR-2000; 2000WO-US09699.
XX
PR   12-APR-1999;   99US-0128849.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Goddard A,  Pan J,  Yan M;
XX
DR   WPI; 2001-070561/08.
DR   P-PSDB; AAB29534.
XX
PT   New isolated nucleic acid encoding a tumor necrosis factor homolog for
PT   modulating apoptosis, NF-kappaB activation, pro-inflammatory or
PT   autoimmune response in mammalian cells -
XX
PS   Claim 27; Fig 3; 82pp; English.
XX
CC   The invention relates to the human tumour necrosis factor receptor
CC   (TNFR) homologues DNA98853 (AAB29533) and DNA101848 (AAB29534), to cDNA
CC   encoding them (AAC63991, AAC63993), and to the complements (AAC63992,
CC   AAC63994) of nucleic acids encoding the TNFR homologues. The invention
CC   also relates to vectors and host cells comprising DNA98853 or DNA101848
CC   nucleic acids, fusion proteins comprising the DNA98853 or DNA101848
CC   proteins, antibodies against the DNA98853 or DNA101848 proteins,
CC   recombinant expression of the DNA98853 or DNA101848 proteins. The
CC   invention further encompasses a method of modulating apoptosis,
CC   NF-kappa-B (nuclear factor kappa-B) activation, or a proinflammatory or
CC   autoimmune response using the DNA98853 or DNA101848 proteins, and a
CC   method of inhibiting or neutralising EDA-A2 protein biological activity
CC   in mammalian cells using DNA98853 or DNA101848-specific antibodies. The
CC   DNA98853 and/or DNA101848 proteins can be used for modulating apoptosis,
CC   NF-kappa-B activation, proinflammatory or autoimmune responses in
CC   mammalian cells. DNA98853 and/or DNA101848 protein immunoadhesins (e.g.,
CC   antibodies) can be used to inhibit or neutralise EDA-A2 protein
CC   biological activity in mammalian cells. DNA98853 and DNA101848
CC   nucleic acids can be used as hybridisation probes in chromosome and gene
CC   mapping, in the generation of antisense RNA and DNA, and in gene
CC   therapy. The present sequence represents cDNA encoding DNA101848 (ATCC
CC   203907).
XX
SQ   Sequence 899 BP; 208 A; 259 C; 239 G; 193 T; 0 other;

  Query Match             87.9%;  Score 609.4;  DB 22;  Length 899;
  Best Local Similarity   99.8%;  Pred. No. 8.7e-173;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 63

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      64 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 123

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           |||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     124 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 183

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     184 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 243

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     244 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 303

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     304 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 363

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     364 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 423

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     424 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 483

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     484 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 543

Qy     541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     544 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 603

Qy     601 GAGTCCCAAGT 611
           ||||||||||||
Db     604 GAGTCCCAAGT 614


RESULT 6
AAC63994/c
ID   AAC63994 standard; cDNA; 899 BP.
XX
AC   AAC63994;
XX
DT   14-FEB-2001  (first entry)
XX
DE   Human TNFR homologue clone DNA101848 cDNA complement.
XX
KW   Human; TNFR homologue; tumour necrosis factor receptor; DNA101848;
KW   apoptosis; NF-kappa-B activation; proinflammatory response;
KW   autoimmune response; modulation; antibody; EDA-A2 inhibition;
KW   gene mapping; antisense therapy; gene therapy; ATCC 203907; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061757-A1.
XX
PD   19-OCT-2000.
XX
PF   12-APR-2000; 2000WO-US09699.
XX
PR   12-APR-1999;   99US-0128849.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Goddard A,  Pan J,  Yan M;
XX
DR   WPI; 2001-070561/08.
DR   P-PSDB; AAB29534.
XX
PT   New isolated nucleic acid encoding a tumor necrosis factor homolog for
PT   modulating apoptosis, NF-kappaB activation, pro-inflammatory or
PT   autoimmune response in mammalian cells -
XX
PS   Claim 27; Fig 3; 82pp; English.
XX
CC   The invention relates to the human tumour necrosis factor receptor
CC   (TNFR) homologues DNA98853 (AAB29533) and DNA101848 (AAB29534), to cDNA
CC   encoding them (AAC63991, AAC63993), and to the complements (AAC63992,
CC   AAC63994) of nucleic acids encoding the TNFR homologues. The invention
CC   also relates to vectors and host cells comprising DNA98853 or DNA101848
CC   nucleic acids, fusion proteins comprising the DNA98853 or DNA101848
CC   proteins, antibodies against the DNA98853 or DNA101848 proteins, The
```

```
CC   invention further encompasses a method of modulating apoptosis,
CC   NF-kappa-B (nuclear factor kappa-B) activation, or a proinflammatory or
CC   autoimmune response using the DNA98853 or DNA101848 proteins, and a
CC   method of inhibiting or neutralising EDA-A2 protein biological activity
CC   in mammalian cells using DNA98853 or DNA101848-specific antibodies. The
CC   DNA98853 and/or DNA101848 proteins can be used for modulating apoptosis,
CC   NF-kappa-B activation, proinflammatory or autoimmune responses in
CC   mammalian cells. DNA98853 and/or DNA101848 protein immunoadhesins (e.g.,
CC   antibodies) can be used to inhibit or neutralise EDA-A2 protein
CC   biological activity in mammalian cells. DNA98853 and DNA101848
CC   nucleic acids can be used as hybridisation probes in chromosome and gene
CC   mapping, in the generation of antisense RNA and DNA, and in gene
CC   therapy. The present sequence represents the complement of cDNA encoding
CC   DNA101848 (ATCC 203907).
XX
SQ   Sequence 899 BP; 193 A; 239 C; 259 G; 208 T; 0 other;

  Query Match             87.9%;  Score 609.4;  DB 22;  Length 899;
  Best Local Similarity   99.8%;  Pred. No. 8.7e-173;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     896 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 837

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     836 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 777

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     776 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 717

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     716 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 657

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     656 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 597

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     596 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 537

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     536 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 477

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     476 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 417

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     416 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 357

Qy     541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     356 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 297

Qy     601 GAGTCCCAAGT 611
          ||||||||||||
Db     296 GAGTCCCAAGT 286


RESULT 7
AAC62232
ID   AAC62232 standard; cDNA; 905 BP.
XX
AC   AAC62232;
XX
DT   06-MAR-2001  (first entry)
XX
DE   cDNA encoding a human DNA98853 polypeptide.
XX
KW   Human; DNA58893; full length inverse polymerase chain reaction; FLIP;
KW   inverse long distance PCR; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             4..903
FT                   /*tag= a
FT                   /product= "DNA98853"
XX
PN   WO200061741-A1.
XX
PD   19-OCT-2000.
XX
PF   10-APR-2000; 2000WO-US09554.
XX
PR   12-APR-1999;   99US-0128849.
PR   10-JAN-2000; 2000US-0480782.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Chui CJ,  Grimaldi JC,  Milton S,  Yan M,  Yi S;
XX
DR   WPI; 2000-679484/66.
DR   P-PSDB; AAB30547.
XX
PT   New polymerase chain based cloning method for isolating a nucleic acid
PT   molecule of interest from a mixture of nucleic acid molecules using
PT   full length inverse PCR -
XX
PS   Example 2; Fig 4; 31pp; English.
XX
CC   The present sequence encodes a human DNA98853 polypeptide. The
CC   DNA98853 gene was amplified and cloned using a PCR-based method of
CC   the invention, called full length inverse polymerase chain reaction
CC   (FLIP). FLIP is also referred to as inverse long distance PCR,
CC   because of its ability to isolate long genes. The specification uses
CC   FLIP for amplifying and isolating a nucleic acid molecule of interest
CC   from a mixture of nucleic acid molecules. The method is useful for
CC   efficiently cloning a wide variety of genes.
XX
SQ   Sequence 905 BP; 210 A; 260 C; 240 G; 195 T; 0 other;

  Query Match             85.6%;  Score 593.4;  DB 21;  Length 905;
  Best Local Similarity   98.9%;  Pred. No. 5.5e-168;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    6;  Gaps    1;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 63

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      64 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 123

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          |||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     124 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 183

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     184 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 243

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     244 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 303

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     304 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 363
```

```
Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     364 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 423

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     424 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 483

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGT------GGAGGTTTGCTGCAGTTT 534
           ||||||||||||||||||||||||||||||||||      ||||||||||||||||||
Db     484 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGTTACAGGAGGTTTGCTGCAGTTT 543

Qy     535 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 594
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     544 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 603

Qy     595 AGTGCTGAGTCCCAAGT 611
           |||||||||||||||||
Db     604 AGTGCTGAGTCCCAAGT 620
```

RESULT 8
AAC58642
ID  AAC58642 standard; cDNA; 905 BP.
XX
AC  AAC58642;
XX
DT  29-JAN-2001  (first entry)
XX
DE  Human PRO5727 protein UNQ2448 encoding cDNA SEQ ID NO:296.
XX
KW  Human; immune related disease; diagnosis; antiinflammatory; cardiant;
KW  dermatological; antiarthritic; antirheumatic; immunosuppressive;
KW  haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
KW  antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
KW  antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;
KW  osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
KW  idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
KW  systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
KW  autoimmune thrombocytopaenia; immune-mediated renal disease;
KW  demyelinating disease; hepatobiliary disease; Whipple's disease;
KW  inflammatory bowel disease; gluten-sensitive enteropathy;
KW  autoimmune disease; immune-mediated skin disease; allergic disease;
KW  immunological disease; transplantation associated disease;
KW  graft rejection; graft-versus-host-disease; ss.
XX
OS  Homo sapiens.
XX
PN  WO200053758-A2.
XX
PD  14-SEP-2000.
XX
PF  02-MAR-2000; 2000WO-US05841.
XX
PR  08-MAR-1999;  99WO-US05028.
PR  10-MAR-1999;  99US-0123618.
PR  12-MAR-1999;  99US-0123957.
PR  23-MAR-1999;  99US-0125775.
PR  12-APR-1999;  99US-0128849.
PR  20-APR-1999;  99WO-US08615.
PR  28-APR-1999;  99US-0131445.
PR  04-MAY-1999;  99US-0132371.
PR  14-MAY-1999;  99US-0134287.
PR  02-JUN-1999;  99WO-US12252.
PR  23-JUN-1999;  99US-0141037.
PR  20-JUL-1999;  99US-0144758.
PR  26-JUL-1999;  99US-0145698.
PR  28-JUL-1999;  99US-0146222.
PR  01-SEP-1999;  99WO-US20111.
PR  08-SEP-1999;  99WO-US20594.
PR  13-SEP-1999;  99WO-US20944.
PR  15-SEP-1999;  99WO-US21090.
PR  15-SEP-1999;  99WO-US21547.
PR  05-OCT-1999;  99WO-US23089.
PR  29-OCT-1999;  99US-0162506.
PR  29-NOV-1999;  99WO-US28214.
PR  30-NOV-1999;  99WO-US28313.
PR  30-NOV-1999;  99WO-US28409.
PR  01-DEC-1999;  99WO-US28301.
PR  01-DEC-1999;  99WO-US28634.
PR  02-DEC-1999;  99WO-US28551.
PR  02-DEC-1999;  99WO-US28564.
PR  02-DEC-1999;  99WO-US28565.
PR  16-DEC-1999;  99WO-US30095.
PR  20-DEC-1999;  99WO-US30999.
PR  30-DEC-1999;  99WO-US31274.
PR  05-JAN-2000; 2000WO-US00219.
PR  06-JAN-2000; 2000WO-US00277.
PR  06-JAN-2000; 2000WO-US00376.
PR  11-FEB-2000; 2000WO-US03565.
PR  18-FEB-2000; 2000WO-US04341.
PR  18-FEB-2000; 2000WO-US04342.
PR  22-FEB-2000; 2000WO-US04414.
XX
PA  (GETH ) GENENTECH INC.
XX
PI  Ashkenazi AJ,  Baker KP,  Goddard A,  Gurney AL,  Hebert C,  Henzel W;
PI  Kabakoff RC,  Lu Y,  Pan J,  Pennica D,  Shelton DL,  Smith V;
PI  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Yan M;
XX
DR  WPI; 2000-572271/53.
DR  P-PSDB; AAB33477.
XX
PT  Sixty four PRO polypeptides, useful in the diagnosis and treatment of
PT  immune related disorders, e.g. systemic lupus erythematosis, rheumatoid
PT  arthritis, osteoarthritis, thyroiditis and diabetes mellitus -
XX
PS  Claim 23; Fig 127; 309pp; English.
XX
CC  The present invention describes sixty four human PRO proteins which can
CC  be used in the treatment of immune related diseases. The human PRO
CC  proteins, anti-PRO antibodies, agonists and antagonists are useful for
CC  treating and diagnosing immune related disorders. The disorders are
CC  selected from systemic lupus erythematosus, rheumatoid arthritis,
CC  osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
CC  systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
CC  syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
CC  anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
CC  immune-mediated renal disease, demyelinating diseases of the central
CC  and peripheral nervous systems, hepatobiliary diseases, inflammatory
CC  bowel disease, gluten-sensitive enteropathy and Whipple's disease,
CC  autoimmune or immune-mediated skin diseases, allergic diseases,
CC  immunological diseases of the lung, and transplantation associated
CC  diseases including graft rejection and graft-versus-host-disease.
CC  AAC58397 to AAC58578 represent PCR primers and hybridisation probes used
CC  in the isolation of human PRO sequences. AAC58579 to AAC58642 and
CC  AAB33414 to AAB33477 represent human PRO polynucleotide and protein
CC  sequences given in the exemplification of the present invention.
XX
SQ  Sequence 905 BP; 210 A; 260 C; 240 G; 195 T; 0 other;

```
  Query Match             85.6%;  Score 593.4;  DB 21;  Length 905;
  Best Local Similarity   98.9%;  Pred. No. 5.5e-168;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    6;  Gaps    1;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 63

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      64 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 123

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
```

```
Db    124 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 183

Qy    181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    184 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 243

Qy    241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    244 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 303

Qy    301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    304 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 363

Qy    361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    364 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 423

Qy    421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    424 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 483

Qy    481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGT------GGAGGTTTGCTGCAGTTT 534
          |||||||||||||||||||||||||||||||||||      ||||||||||||||||||
Db    484 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGTTACAGGAGGTTTGCTGCAGTTT 543

Qy    535 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 594
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    544 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 603

Qy    595 AGTGCTGAGTCCCAAGT 611
          |||||||||||||||||
Db    604 AGTGCTGAGTCCCAAGT 620


RESULT 9
AAC63991
ID   AAC63991 standard; cDNA; 905 BP.
XX
AC   AAC63991;
XX
DT   14-FEB-2001  (first entry)
XX
DE   Human TNFR homologue clone DNA98853 cDNA.
XX
KW   Human; TNFR homologue; tumour necrosis factor receptor; DNA98853;
KW   apoptosis; NF-kappa-B activation; proinflammatory response;
KW   autoimmune response; modulation; antibody; EDA-A2 inhibition;
KW   gene mapping; antisense therapy; gene therapy; ATCC 203906; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061757-A1.
XX
PD   19-OCT-2000.
XX
PF   12-APR-2000; 2000WO-US09699.
XX
PR   12-APR-1999;   99US-0128849.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Goddard A,  Pan J,  Yan M;
XX
DR   WPI; 2001-070561/08.
DR   P-PSDB; AAB29533.
XX
PT   New isolated nucleic acid encoding a tumor necrosis factor homolog for
PT   modulating apoptosis, NF-kappaB activation, pro-inflammatory or
PT   autoimmune response in mammalian cells -
XX
PS   Claim 2; Fig 1; 82pp; English.
XX
CC   The invention relates to the human tumour necrosis factor receptor
CC   (TNFR) homologues DNA98853 (AAB29533) and DNA101848 (AAB29534), to cDNA
CC   encoding them (AAC63991, AAC63993), and to the complements (AAC63992,
CC   AAC63994) of nucleic acids encoding the TNFR homologues. The invention
CC   also relates to vectors and host cells comprising DNA98853 or DNA101848
CC   nucleic acids, fusion proteins comprising the DNA98853 or DNA101848
CC   proteins, antibodies against the DNA98853 or DNA101848 proteins,
CC   recombinant expression of the DNA98853 or DNA101848 proteins. The
CC   invention further encompasses a method of modulating apoptosis,
CC   NF-kappa-B (nuclear factor kappa-B) activation, or a proinflammatory or
CC   autoimmune response using the DNA98853 or DNA101848 proteins, and a
CC   method of inhibiting or neutralising EDA-A2 protein biological activity
CC   in mammalian cells using DNA98853 or DNA101848-specific antibodies. The
CC   DNA98853 and/or DNA101848 proteins can be used for modulating apoptosis,
CC   NF-kappa-B activation, proinflammatory or autoimmune responses in
CC   mammalian cells. DNA98853 and/or DNA101848 protein immunoadhesins (e.g.,
CC   antibodies) can be used to inhibit or neutralise EDA-A2 protein
CC   biological activity in mammalian cells. DNA98853 and DNA101848
CC   nucleic acids can be used as hybridisation probes in chromosome and gene
CC   mapping, in the generation of antisense RNA and DNA, and in gene
CC   therapy. The present sequence represents cDNA encoding DNA98853 (ATCC
CC   203906).
XX
SQ   Sequence 905 BP; 210 A; 260 C; 240 G; 195 T; 0 other;

  Query Match             85.6%;  Score 593.4;  DB 22;  Length 905;
  Best Local Similarity   98.9%;  Pred. No. 5.5e-168;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    6;  Gaps    1;

Qy      1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      4 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 63

Qy     61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     64 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 123

Qy    121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          |||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db    124 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 183

Qy    181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    184 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 243

Qy    241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    244 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 303

Qy    301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    304 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 363

Qy    361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    364 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 423

Qy    421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    424 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 483

Qy    481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGT------GGAGGTTTGCTGCAGTTT 534
          |||||||||||||||||||||||||||||||||||      ||||||||||||||||||
Db    484 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGTTACAGGAGGTTTGCTGCAGTTT 543

Qy    535 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 594
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    544 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 603

Qy    595 AGTGCTGAGTCCCAAGT 611
          |||||||||||||||||
Db    604 AGTGCTGAGTCCCAAGT 620
```

```
RESULT 10
AAC63992/c
ID   AAC63992 standard; cDNA; 905 BP.
XX
AC   AAC63992;
XX
DT   14-FEB-2001  (first entry)
XX
DE   Human TNFR homologue clone DNA98853 cDNA complement.
XX
KW   Human; TNFR homologue; tumour necrosis factor receptor; DNA98853;
KW   apoptosis; NF-kappa-B activation; proinflammatory response;
KW   autoimmune response; modulation; antibody; EDA-A2 inhibition;
KW   gene mapping; antisense therapy; gene therapy; ATCC 203906; ss.
XX
OS   Homo sapiens.
XX
PN   WO200061757-A1.
XX
PD   19-OCT-2000.
XX
PF   12-APR-2000; 2000WO-US09699.
XX
PR   12-APR-1999;   99US-0128849.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Goddard A,  Pan J,  Yan M;
XX
DR   WPI; 2001-070561/08.
DR   P-PSDB; AAB29533.
XX
PT   New isolated nucleic acid encoding a tumor necrosis factor homolog for
PT   modulating apoptosis, NF-kappaB activation, pro-inflammatory or
PT   autoimmune response in mammalian cells -
XX
PS   Claim 2; Fig 1; 82pp; English.
XX
CC   The invention relates to the human tumour necrosis factor receptor
CC   (TNFR) homologues DNA98853 (AAB29533) and DNA101848 (AAB29534), to cDNA
CC   encoding them (AAC63991, AAC63993), and to the complements (AAC63992,
CC   AAC63994) of nucleic acids encoding the TNFR homologues. The invention
CC   also relates to vectors and host cells comprising DNA98853 or DNA101848
CC   nucleic acids, fusion proteins comprising the DNA98853 or DNA101848
CC   proteins, antibodies against the DNA98853 or DNA101848 proteins,
CC   recombinant expression of the DNA98853 or DNA101848 proteins. The
CC   invention further encompasses a method of modulating apoptosis,
CC   NF-kappa-B (nuclear factor kappa-B) activation, or a proinflammatory or
CC   autoimmune response using the DNA98853 or DNA101848 proteins, and a
CC   method of inhibiting or neutralising EDA-A2 protein biological activity
CC   in mammalian cells using DNA98853 or DNA101848-specific antibodies. The
CC   DNA98853 and/or DNA101848 proteins can be used for modulating apoptosis,
CC   NF-kappa-B activation, proinflammatory or autoimmune responses in
CC   mammalian cells. DNA98853 and/or DNA101848 protein immunoadhesins (e.g.,
CC   antibodies) can be used to inhibit or neutralise EDA-A2 protein
CC   biological activity in mammalian cells. DNA98853 and DNA101848
CC   nucleic acids can be used as hybridisation probes in chromosome and gene
CC   mapping, in the generation of antisense RNA and DNA, and in gene
CC   therapy. The present sequence represents the complement of the cDNA
CC   encoding DNA98853 (ATCC 203906).
XX
SQ   Sequence 905 BP; 195 A; 240 C; 260 G; 210 T; 0 other;

  Query Match             85.6%;  Score 593.4;  DB 22;  Length 905;
  Best Local Similarity   98.9%;  Pred. No. 5.5e-168;
  Matches  610;  Conservative    0;  Mismatches    1;  Indels    6;  Gaps    1;

Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     902 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 843

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     842 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 783

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     782 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAGATGTCAGAGT 723

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     722 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 663

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     662 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 603

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     602 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 543

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     542 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 483

Qy     421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     482 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 423

Qy     481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGT------GGAGGTTTGCTGCAGTTT 534
           |||||||||||||||||||||||||||||||||||      ||||||||||||||||||
Db     422 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGTTACAGGAGGTTTGCTGCAGTTT 363

Qy     535 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 594
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     362 GAGGCTGATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACC 303

Qy     595 AGTGCTGAGTCCCAAGT 611
           |||||||||||||||||
Db     302 AGTGCTGAGTCCCAAGT 286


RESULT 11
AAA47453
ID   AAA47453 standard; cDNA; 1550 BP.
XX
AC   AAA47453;
XX
DT   20-OCT-2000  (first entry)
XX
DE   Human TANGO 140-1 coding sequence.
XX
KW   TANGO; 128; 140; 197; 212; 213; 224; 239; modulating agent; asthma;
KW   graft versus-host diseases; rheumatoid arthritis; psoriasis;
KW   inflammatory bowel disease; septic shock; ulcerative colitis;
KW   Crohn's disease; chronic myelogenous leukemia; cancer; liver
KW   disease; Hodgkin's disease; osteoarthritis; Lyme's disease;
KW   cachexia; autoimmune disease; myasthemia gravis; autoimmune diabetes;
KW   systemic lupus erythematosus; transgenic animal; diagnosis;
KW   prognosis; prophylatic; therapeutic; human; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             2..622
FT                   /*tag= a
FT                   /product= TANGO 140-1
XX
PN   WO200039284-A1.
XX
PD   06-JUL-2000.
XX
PF   23-DEC-1999;   99WO-US31025.
XX
PR   30-DEC-1998;   98US-0223546.
```

XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Holtzman DA;
XX
DR WPI; 2000-465743/40.
DR P-PSDB; AAB01420.
XX
PT Novel nucleic acid sequences encoding TANGO-128, 140, 197, 212, 213,
PT 224 and 239 polypeptides useful for the treatment of asthma, rheumatoid
PT arthritis, psoriasis and autoimmune diseases
XX
PS Claim 1; Fig 2; 209pp; English.
XX
CC Nucleic acids encoding TANGO polypeptides are useful as modulating
CC agents for regulating cellular processes like asthma, graft
CC versus-host diseases, rheumatoid arthritis, psoriasis, inflammatory
CC bowel disease, septic shock, ulcerative colitis, Crohn's disease,
CC chronic myelogenous leukemia, cancer, liver disease, Hodgkin's
CC disease, osteoarthritis, Lyme's disease, cachexia and autoimmune
CC diseases e.g. myasthemia gravis, autoimmune diabetes and systemic
CC lupus erythematosus. The nucleic acids are also useful for producing
CC transgenic animals and the TANGO polypeptides themselves. Partial
CC TANGO-128, 140, 197, 212, 213, 224, 239 sequences are useful in
CC forensic biology, for diagnostic assays, prognostic assays,
CC pharmacogenomics and for monitoring clinical trials. TANGO
CC polypeptides are suitable for both prophylactic and therapeutic
CC methods for treating a subject at risk of a disorder or having a
CC disorder associated with aberrant TANGO expression. A wide range
CC of cellular disorders can be treated.
XX
SQ Sequence 1550 BP; 452 A; 329 C; 392 G; 377 T; 0 other;

Query Match 74.7%; Score 518; DB 21; Length 1550;
Best Local Similarity 100.0%; Pred. No. 3.1e-145;
Matches 518; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     26 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 85

Qy     61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     86 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 145

Qy    121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    146 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 205

Qy    181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    206 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 265

Qy    241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    266 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 325

Qy    301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    326 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 385

Qy    361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    386 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 445

Qy    421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    446 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 505

Qy    481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGG 518
          ||||||||||||||||||||||||||||||||||||||
Db    506 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGG 543
```

RESULT 12
AAS05960
ID AAS05960 standard; cDNA; 891 BP.
XX
AC AAS05960;
XX
DT 07-SEP-2001 (first entry)
XX
DE Degenerate cDNA sequence for human UMLR variant #1.
XX
KW Human; uterine myometrium leiomyoma receptor; UMLR; ztnfr11;
KW tumour necrosis factor receptor; TNFR; chromosome Xq11-q12; lung cancer;
KW breast carcinoma; uterus melanoma; osteosarcoma; lymphoma; wound healing;
KW gene therapy; ss.
XX
OS Homo sapiens.
XX
PN WO200130850-A1.
XX
PD 03-MAY-2001.
XX
PF 23-OCT-2000; 2000WO-US29304.
XX
PR 22-OCT-1999; 99US-0160880.
PR 02-NOV-1999; 99US-0163215.
PR 17-JUL-2000; 2000US-0218769.
PR 01-AUG-2000; 2000US-0222221.
XX
PA (ZYMO ) ZYMOGENETICS INC.
XX
PI Xu W, Lofton-Day CE, Henne R, Presnell SR, Yao Y, Novak JE;
PI Foster DC, Yee DP;
XX
DR WPI; 2001-300488/31.
XX
PT Uterine myometrium leiomyoma receptor polypeptides and polynucleotides
PT for modulating inflammation, tumour growth, metastasis, cellular
PT maturation, detecting modulators and as diagnostic indicators of cancer
PT -
XX
PS Example 12; Page 133; 148pp; English.
XX
CC The present sequence represents a degenerate cDNA sequence for human
CC uterine myometrium leiomyoma receptor (UMLR) variant #1. UMLR is a novel
CC member of the tumour necrosis factor receptor (TNFR) family. The UMLR
CC (also known as ztnfr11) gene maps to chromosome Xq11-q12. Amino acid
CC residues of UMLR involved in ligand binding, consisting of residues 1-X
CC (where X is 129-136) are useful for inhibiting the quantity of lung,
CC breast carcinoma, melanoma, osteosarcoma or lymphoma cells expressing
CC UMLR protein. UMLR polypeptides or its fragments are useful
CC diagnostically or therapeutically for identifying tumour cells in uterus
CC melanoma and lung cancer, for promoting wound healing, and for generating
CC vaccines for cancer therapy. They are also useful for studying cell-cell
CC interactions, apoptosis, fertilisation, development, immune recognition,
CC growth control, tumour suppression and embryo maturation in vitro and in
CC vivo, and for treating disorders associated with them. UMLR is also
CC useful for identifying inhibitors of its activity, and for preparing
CC antibodies which can be used to detect UMLR expression. UMLR
CC polynucleotide sequences are useful as probes or primers as diagnostic
CC indicators of cancer and for gene therapy.
XX
SQ Sequence 891 BP; 141 A; 105 C; 150 G; 112 T; 383 other;

Query Match 64.4%; Score 446.6; DB 22; Length 891;
Best Local Similarity 58.6%; Pred. No. 6.7e-124;
Matches 360; Conservative 147; Mismatches 107; Indels 0; Gaps 0;

```
Qy      1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
          |||||:||:||:||:||:||:||:|||||:||:||||| :| ||:|| || ||:||::|
Db      1 ATGGAYTGYCARGARAAYGARTAYTGGGAYCARTGGGGNMGNTGYGTNACNTGYCARMGN 60

Qy     61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
```

```
Db     61 TGYGGNCCNGGNCARGARYTNWSNAARGAYTGYGGNTAYGGNGARGGNGGNGAYGCNTAY 120

Qy    121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
Db    121 TGYACNGCNTGYCCNCCNMGNMGNTAYAARWSNWSNTGGGGNCAYCAYAARTGYCARWSN 180

Qy    181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
Db    181 TGYATHACNTGYGCNGTNATHAAYMGNGTNCARAARGTNAAYTGYACNGCNACNWSNAAY 240

Qy    241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
Db    241 GCNGTNTGYGGNGAYTGYYTNCCNMGNTTYTAYMGNAARACNMGNATHGGNGGNYTNCAR 300

Qy    301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
Db    301 GAYCARGARTGYATHCCNTGYACNAARCARACNCCNACNWSNGARGTNCARTGYGCNTTY 360

Qy    361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
Db    361 CARYTNWSNYTNGTNGARGCNGAYGCNCCNACNGTNCCNCCNCARGARGCNACNYTNGTN 420

Qy    421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
Db    421 GCNYTNGTNWSNWSNYTNYTNGTNGTNTTYACNYTNGCNTTYYTNGGNYTNTTYTTYTN 480

Qy    481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
Db    481 TAYTGYAARCARTTYTTYAAYMGNCAYTGYCARMGNGGNGGNYTNYTNCARTTYGARGCN 540

Qy    541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
Db    541 GAYAARACNGCNAARGARGARWSNYTNTTYCCNGTNCCNCCNWSNAARGARACNWSNGCN 600

Qy    601 GAGTCCCAAGTCTC 614
Db    601 GARWSNCARGTNWS 614
```

RESULT 13
AAS05945

```
ID   AAS05945 standard; cDNA; 807 BP.
XX
AC   AAS05945;
XX
DT   07-SEP-2001  (first entry)
XX
DE   Human uterine myometrium leiomyoma receptor (UMLR) degenerate sequence.
XX
KW   Human; uterine myometrium leiomyoma receptor; UMLR; ztnfr11;
KW   tumour necrosis factor receptor; TNFR; chromosome Xq11-q12; lung cancer;
KW   breast carcinoma; uterus melanoma; osteosarcoma; lymphoma; wound healing;
KW   gene therapy; ss.
XX
OS   Homo sapiens.
XX
PN   WO200130850-A1.
XX
PD   03-MAY-2001.
XX
PF   23-OCT-2000; 2000WO-US29304.
XX
PR   22-OCT-1999;   99US-0160880.
PR   02-NOV-1999;   99US-0163215.
PR   17-JUL-2000; 2000US-0218769.
PR   01-AUG-2000; 2000US-0222221.
XX
PA   (ZYMO ) ZYMOGENETICS INC.
XX
PI   Xu W, Lofton-Day CE, Henne R, Presnell SR, Yao Y, Novak JE;
PI   Foster DC, Yee DP;
XX
DR   WPI; 2001-300488/31.
XX
PT   Uterine myometrium leiomyoma receptor polypeptides and polynucleotides
PT   for modulating inflammation, tumour growth, metastasis, cellular
PT   maturation, detecting modulators and as diagnostic indicators of cancer
PT   -
XX
PS   Disclosure; Page 117-118; 148pp; English.
XX
CC   The present sequence represents a degenerate sequence encoding for a
CC   novel human uterine myometrium leiomyoma receptor (UMLR) which is a
CC   member of the tumour necrosis factor receptor (TNFR) family. The UMLR
CC   (also known as ztnfr11) gene maps to chromosome Xq11-q12. Amino acid
CC   residues of UMLR involved in ligand binding, consisting of residues 1-X
CC   (where X is 129-136) are useful for inhibiting the quantity of lung,
CC   breast carcinoma, melanoma, osteosarcoma or lymphoma cells expressing
CC   UMLR protein. UMLR polypeptides or its fragments are useful
CC   diagnostically or therapeutically for identifying tumour cells in uterus
CC   melanoma and lung cancer, for promoting wound healing, and for generating
CC   vaccines for cancer therapy. They are also useful for studying cell-cell
CC   interactions, apoptosis, fertilisation, development, immune recognition,
CC   growth control, tumour suppression and embryo maturation in vitro and in
CC   vivo, and for treating disorders associated with them. UMLR is also
CC   useful for identifying inhibitors of its activity, and for preparing
CC   antibodies which can be used to detect UMLR expression. UMLR
CC   polynucleotide sequences are useful as probes or primers as diagnostic
CC   indicators of cancer and for gene therapy.
XX
SQ   Sequence 807 BP; 125 A; 93 C; 142 G; 102 T; 345 other;
```

Query Match 64.4%; Score 446.4; DB 22; Length 807;
Best Local Similarity 55.4%; Pred. No. 7.3e-124;
Matches 370; Conservative 156; Mismatches 142; Indels 0; Gaps 0;

```
Qy      1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
Db      1 ATGGAYTGYCARGARAAYGARTAYTGGGAYCARTGGGGNMGNTGYGTNACNTGYCARMGN 60

Qy     61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
Db     61 TGYGGNCCNGGNCARGARYTNWSNAARGAYTGYGGNTAYGGNGARGGNGGNGAYGCNTAY 120

Qy    121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
Db    121 TGYACNGCNTGYCCNCCNMGNMGNTAYAARWSNWSNTGGGGNCAYCAYAARTGYCARWSN 180

Qy    181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
Db    181 TGYATHACNTGYGCNGTNATHAAYMGNGTNCARAARGTNAAYTGYACNGCNACNWSNAAY 240

Qy    241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
Db    241 GCNGTNTGYGGNGAYTGYYTNCCNMGNTTYTAYMGNAARACNMGNATHGGNGGNYTNCAR 300

Qy    301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
Db    301 GAYCARGARTGYATHCCNTGYACNAARCARACNCCNACNWSNGARGTNCARTGYGCNTTY 360

Qy    361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
Db    361 CARYTNWSNYTNGTNGARGCNGAYGCNCCNACNGTNCCNCCNCARGARGCNACNYTNGTN 420

Qy    421 GCACTGGTGAGCAGCCTGCTAGTGGTGTTTACCCTGGCCTTCCTGGGGCTCTTCTTCCTC 480
Db    421 GCNYTNGTNWSNWSNYTNYTNGTNGTNTTYACNYTNGCNTTYYTNGGNYTNTTYTTYTN 480

Qy    481 TACTGCAAGCAGTTCTTCAACAGACATTGCCAGCGTGGAGGTTTGCTGCAGTTTGAGGCT 540
Db    481 TAYTGYAARCARTTYTTYAAYMGNCAYTGYCARMGNGGNGGNYTNYTNCARTTYGARGCN 540

Qy    541 GATAAAACAGCAAAGGAGGAATCTCTCTTCCCCGTGCCACCCAGCAAGGAGACCAGTGCT 600
Db    541 GAYAARACNGCNAARGARGARWSNYTNTTYCCNGTNCCNCCNWSNAARGARACNWSNGCN 600
```

```
Qy     601 GAGTCCCAAGTCTCTTGGGCCCCTGGCAGCCTTGCCCAGTTGTTCTCTCTGGACTCTGTT 660
           ||::: ||:|  :: |   |    |  ::   : |      ::    :    |:|  ||
Db     601 GARWSNCARGARWSNTTYACNATGGCNWSNTGYACNWSNGARWSNCAYWSNCAYTGGGTN 660

Qy     661 CCTATACC 668
           | ::  ||
Db     661 CAYWSNCC 668
```

RESULT 14
AAA47454
ID  AAA47454 standard; cDNA; 3385 BP.
XX
AC  AAA47454;
XX
DT  20-OCT-2000  (first entry)
XX
DE  Human TANGO 140-2 coding sequence.
XX
KW  TANGO; 128; 140; 197; 212; 213; 224; 239; modulating agent; asthma;
KW  graft versus-host diseases; rheumatoid arthritis; psoriasis;
KW  inflammatory bowel disease; septic shock; ulcerative colitis;
KW  Crohn's disease; chronic myelogenous leukemia; cancer; liver
KW  disease; Hodgkin's disease; osteoarthritis; Lyme's disease;
KW  cachexia; autoimmune disease; myasthemia gravis; autoimmune diabetes;
KW  systemic lupus erythematosus; transgenic animal; diagnosis;
KW  prognosis; prophylatic; therapeutic; human; ds.
XX
OS  Homo sapiens.
XX
FH  Key             Location/Qualifiers
FT  CDS             1..594
FT                  /*tag=  a
FT                  /product= TANGO 140-2
XX
PN  WO200039284-A1.
XX
PD  06-JUL-2000.
XX
PF  23-DEC-1999;  99WO-US31025.
XX
PR  30-DEC-1998;  98US-0223546.
XX
PA  (MILL-) MILLENNIUM PHARM INC.
XX
PI  Holtzman DA;
XX
DR  WPI; 2000-465743/40.
DR  P-PSDB; AAB01421.
XX
PT  Novel nucleic acid sequences encoding TANGO-128, 140, 197, 212, 213,
PT  224 and 239 polypeptides useful for the treatment of asthma, rheumatoid
PT  arthritis, psoriasis and autoimmune diseases
XX
PS  Claim 1; Fig 3; 209pp; English.
XX
CC  Nucleic acids encoding TANGO polypeptides are useful as modulating
CC  agents for regulating cellular processes like asthma, graft
CC  versus-host diseases, rheumatoid arthritis, psoriasis, inflammatory
CC  bowel disease, septic shock, ulcerative colitis, Crohn's disease,
CC  chronic myelogenous leukemia, cancer, liver disease, Hodgkin's
CC  disease, osteoarthritis, Lyme's disease, cachexia and autoimmune
CC  diseases e.g. myasthemia gravis, autoimmune diabetes and systemic
CC  lupus erythematosus. The nucleic acids are also useful for producing
CC  transgenic animals and the TANGO polypeptides themselves. Partial
CC  TANGO-128, 140, 197, 212, 213, 224, 239 sequences are useful in
CC  forensic biology, for diagnostic assays, prognostic assays,
CC  pharmacogenomics and for monitoring clinical trials. TANGO
CC  polypeptides are suitable for both prophylactic and therapeutic
CC  methods for treating a subject at risk of a disorder or having a
CC  disorder associated with aberrant TANGO expression. A wide range
CC  of cellular disorders can be treated.
XX
SQ  Sequence 3385 BP; 915 A; 801 C; 718 G; 951 T; 0 other;

  Query Match           61.7%;  Score 427.4;  DB 21;  Length 3385;
  Best Local Similarity  99.8%;  Pred. No. 7e-118;
  Matches  428;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

```
Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      67 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 126

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     127 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 186

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     187 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 246

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     247 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 306

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     307 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 366

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     367 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 426

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     427 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTGTT 486

Qy     421 GCACTGGTG 429
           ||||||  ||
Db     487 GCACTGTTG 495
```

RESULT 15
AAS05973
ID  AAS05973 standard; DNA; 1081 BP.
XX
AC  AAS05973;
XX
DT  07-SEP-2001  (first entry)
XX
DE  Expression vector pZP7Z insert sequence containing ztnfr11/TNFR1 chimera.
XX
KW  Mouse; uterine myometrium leiomyoma receptor; UMLR; ztnfr11;
KW  tumour necrosis factor receptor; TNFR; chromosome Xq11-q12; lung cancer;
KW  breast carcinoma; uterus melanoma; osteosarcoma; lymphoma; wound healing;
KW  gene therapy; human; mutant; ds.
XX
OS  Chimeric - Mus sp.
OS  Chimeric - Homo sapiens.
OS  Synthetic.
XX
PN  WO200130850-A1.
XX
PD  03-MAY-2001.
XX
PF  23-OCT-2000; 2000WO-US29304.
XX
PR  22-OCT-1999;  99US-0160880.
PR  02-NOV-1999;  99US-0163215.
PR  17-JUL-2000; 2000US-0218769.
PR  01-AUG-2000; 2000US-0222221.
XX
PA  (ZYMO ) ZYMOGENETICS INC.
XX
PI  Xu W,  Lofton-Day CE,  Henne R,  Presnell SR,  Yao Y,  Novak JE;

PI Foster DC, Yee DP;
XX
DR WPI; 2001-300488/31.
XX
PT Uterine myometrium leiomyoma receptor polypeptides and polynucleotides
PT for modulating inflammation, tumour growth, metastasis, cellular
PT maturation, detecting modulators and as diagnostic indicators of cancer
PT -
XX
PS Example 14; Page 143-144; 148pp; English.
XX
CC The present sequence for expression vector pZP7Z insert sequence
CC contains the sequence for a ztnfrl1/TNFR1 chimera and the KZ159/mIL4
CC reporter gene sequence. Human ztnfrl1 or UMLR (uterine myometrium
CC leiomyoma receptor is a novel member of the tumour necrosis factor
CC receptor (TNFR) family. The UMLR (also known as ztnfrl1) gene maps
CC to chromosome Xq11-q12. Amino acid residues of UMLR involved in ligand
CC binding, consisting of residues 1-X (where X is 129-136) are useful for
CC inhibiting the quantity of lung, breast carcinoma, melanoma, osteosarcoma
CC or lymphoma cells expressing UMLR protein. UMLR polypeptides or its
CC fragments are useful diagnostically or therapeutically for identifying
CC tumour cells in uterus melanoma and lung cancer, for promoting wound
CC healing, and for generating vaccines for cancer therapy. They are also
CC useful for studying cell-cell interactions, apoptosis, fertilisation,
CC development, immune recognition, growth control, tumour suppression and
CC embryo maturation in vitro and in vivo, and for treating disorders
CC associated with them. UMLR is also useful for identifying inhibitors of
CC its activity, and for preparing antibodies which can be used to detect
CC UMLR expression. UMLR polynucleotide sequences are useful as probes or
CC primers as diagnostic indicators of cancer and for gene therapy.
XX
SQ Sequence 1081 BP; 248 A; 311 C; 306 G; 216 T; 0 other;

Query Match 59.6%; Score 413.2; DB 22; Length 1081;
Best Local Similarity 99.3%; Pred. No. 7.8e-114;
Matches 415; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
Qy       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 ATGGATTGCCAAGAAAATGAGTACTGGGACCAATGGGGACGGTGTGTCACCTGCCAACGG 60

Qy      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 TGTGGTCCTGGACAGGAGCTATCCAAGGATTGTGGTTATGGAGAGGGTGGAGATGCCTAC 120

Qy     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 TGCACAGCCTGCCCTCCTCGCAGGTACAAAAGCAGCTGGGGCCACCACAAATGTCAGAGT 180

Qy     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     181 TGCATCACCTGTGCTGTCATCAATCGTGTTCAGAAGGTCAACTGCACAGCTACCTCTAAT 240

Qy     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     241 GCTGTCTGTGGGGACTGTTTGCCCAGGTTCTACCGAAAGACACGCATTGGAGGCCTGCAG 300

Qy     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     301 GACCAAGAGTGCATCCCGTGCACGAAGCAGACCCCCACCTCTGAGGTTCAATGTGCCTTC 360

Qy     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGCCACACTTG 418
           |||||||||||||||||||||||||||||||||||||||||||| |||  |||
Db     361 CAGTTGAGCTTAGTGGAGGCAGATGCACCCACAGTGCCCCCTCAGGAGGTCACCGTTG 418
```

Search completed: October 27, 2002, 01:37:17
Job time : 250 secs